Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-06-14
2005-06-14
Fredman, Jeffrey (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
06905821
ABSTRACT:
The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing Dihydropyrimidine dehydrogenase (DPD) expression levels in tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU based therapies by examination of the amount of DPD mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pairs DPD3A and DPD3B and methods comprising their use for detecting levels of Dihydropyrimidine dehydrogenase (DPD) mRNA.
REFERENCES:
patent: 4830969 (1989-05-01), Holmes
patent: 4843155 (1989-06-01), Chomczynski
patent: 5128247 (1992-07-01), Koller
patent: 5284940 (1994-02-01), Lin et al.
patent: 5346994 (1994-09-01), Chomczynski
patent: 5502166 (1996-03-01), Mishina
patent: 5620852 (1997-04-01), Lin et al.
patent: 5637687 (1997-06-01), Wiggins
patent: 5643767 (1997-07-01), Fischetti et al.
patent: 5654179 (1997-08-01), Lin
patent: 5672696 (1997-09-01), Wang et al.
patent: 5707802 (1998-01-01), Sandhu et al.
patent: 5728822 (1998-03-01), Macfarlane
patent: 5736531 (1998-04-01), Von Borstel et al.
patent: 5777099 (1998-07-01), Mehra
patent: 5856454 (1999-01-01), Gonzalez et al.
patent: 5945515 (1999-08-01), Chomczynski
patent: 5989857 (1999-11-01), Mundschenk
patent: 6010700 (2000-01-01), Richt
patent: 6015673 (2000-01-01), Gonzalez et al.
patent: 6043354 (2000-03-01), Hillebrand et al.
patent: 6204375 (2001-03-01), Lader
patent: 6207408 (2001-03-01), Essenfeld et al.
patent: 6232448 (2001-05-01), Yoshikubo et al.
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 198 37 391 (1999-02-01), None
patent: WO 95/28489 (1995-10-01), None
patent: WO 96/08568 (1996-03-01), None
patent: WO 97/05248 (1997-02-01), None
patent: WO 97/35034 (1997-09-01), None
patent: WO 98/41648 (1998-09-01), None
patent: WO 02/44423 (2002-06-01), None
Wlllhauck et al, “Internal control for quality assurance of Diagnostic RT-PCR”, Biotechniques (Oct. 1998) 25(4):656-659.
Selvey et al, B-Actin an unsuitable internal control for RT-PCR (Mol. Cell. Probes (2001) 15:307-311).
Stanta et al (Biotechniques (1991) 11(3):303, 306, 308).
G. Stanta, et al.,RNA Quantitative Analysis from Fixed and Paraffin-Embedded Tissues, Methods in Molecular Biology (1998) vol. 86, pp. 113-119.
G. Stanta, et al.,RNA Extraction from Formalin-Fixed and Paraffin-Embedded Tissues, Methods in Molecular Biology (1998) vol. 86, pp. 23-26.
Iqbal S, Lenz HJ, “Determinants of prognosis and response to therapy in colorectal cancer,”Curr Oncol Rep. Mar. 2001;(3(2):102-8.
Gilmore PM, et al., “The Development and Optimisation of a Quantitative RT-PCR Technique from Formalin-Fixed and Paraffin-Embedded (FFPE) Tissues, Using the Thymidylate Synthase (TS) Gene As a Target,” American Society of Clinical Oncology: 17: Abstract 2159, 1998.
Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K, “Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer,” J Clin Oncol. Dec. 1, 2000;18(23):3946-51.
Takabayashi A, Iwata S, Kawai Y, Kanai M, Taki Y, Takechi T, Fukushima M., “Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy,” Int J Oncol. Nov. 2000;17(5):889-95.
Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV, “Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase,” Clin Cancer Res. Apr. 2000;6(4):1322-7.
Nishiyama M, Yamamoto W, Park JS, Okamoto R, Hanaoka H, Takano H, Saito N, Matsukawa M, Shirasaka T, Kurihara M, “Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves,” Clin Cancer Res. Sep. 1999;5(9):2620-8.
Kirihara Y, Yamamoto W, Toge T, Nishiyama M, “Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells,” Int J Oncol. Mar. 1999;14(3):551-6.
Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T, “Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer,” Hepatogastroenterology, Nov.-Dec. 1998;45(24):2117-22.
Ishikawa et al., “Dehydrogenase activity and messenger RNA level may be related to the antitumor effects of 5-FU on human tumor xenografts in nude mice,” Clin. Cancer Res., 5:883-889, 1999.
Johnson et al, “Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction,” Analyt. Biochem. 278: 175-184, 2000.
Shirota Y, Ichikawa W, Yamada H, Uetake H, Nihei Z, Sugihara K, “Dihydropyrimidine dehydrogenase gene expression in patients with hepatic metastases from colorectal cancer,”Gan To Kagaku Ryoho Oct. 1999; 26(12):1729-31.
Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H, “Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue,” Am J Pathol. Feb. 2001;158(2):419-2.
Gibson, UE, “A novel method for real timequantitative RT-PCR,” Genome Res 6: 995-1001, 1996.
Heid, CA, “Real Time quantitative PCR,” Genome Res 6: 986-994, 1996.
Leichman et al., Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. Oct. 1997;15(10):3223-9.
Harris et al., Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. Jan. 1, 1990;50(1):197-201.
Etienne et al., Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. Jul. 1995;13(7):1663-70.
Beck et al., A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994;30A(10):1517-224.
Johnston et al., TS Expression from Formalin Fixed Paraffin Embedded (FFPE) tissues using Quantitative RT-PCR correlates with frozen tissue data and predicts for response to 5-FU in metastatic colorectal cancers. American Society of Clinical Oncology: Astract 2383, 1999.
Ichikawa et al., Expression of DPD in primary lesion predicts the anti-tumor effect in 5-FU based Chemotherapy gor GI tract cancer. American Society of Clinical Oncology: Astract 1114, 2000.
Danenberg et al., DPD and TS expressions identify a high percentage of colorectal tumors responding to 5-FU. American Society of Clinical Oncology: Astract 992, 1998.
Nihei, Z., Expression of Dihydropyrimidine Dehydrogenase (DPD) in Gastric Cancer, 36thAnnual Meeting of the American Scoeity of Clinical Oncology, Gastric Cancer, 1176, May 20-23, 2000.
Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M., Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.Jpn J Cancer Res. Jan. 2000;91(1):105-12.
Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M., Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res. Nov.-Dec. 1999;19(6C):5635-40.
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, An
Fredman Jeffrey
Response Genetics, Inc.
LandOfFree
Method of determining Dihydropyrimidine dehydrogenase gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining Dihydropyrimidine dehydrogenase gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining Dihydropyrimidine dehydrogenase gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494270